title: [Dyshidrosis and acral purpura during polymorphic dermatitis in pregnancy: 2 cases].
abstract: BACKGROUND
  We describe two severe cases of polymorphic eruption of pregnancy associated with dyshidrosis and purpuric lesions.
  
  
  METHODS
  Two patients, primigravida at 35 and 34 weeks of amenorrhea, were admitted in our department for a severe and itchy eruption. In the first case, some papular lesions were particularly concentrated on the abdominal striae, associated with vesicles on the limbs. There were plantar dyshidrosis and purpuric macules on the toes. In the second case, there were a maculopapular eruption on the abdomen and limbs, some vesicles and bullae of palms and soles, and a purpura of heels. In both cases, the skin biopsy showed dermic inflammatory, direct immunofluorescence and Pemphigoide Gestationis Factor research were negatives. The two patients were treated with betamethasone dipropionate (Diprosone(R)), and hydroxyzine (Atarax(R)). They gave birth to healthy babies.
  
  
  CONCLUSIONS
  Dyshidrosis is not exceptional in polymorphic eruption of pregnancy. Indeed, in the several series of polymorphic eruption of pregnancy we checked, a pompholyx distribution was observed in 5 p. 100 of the cases. It is not necessary a sign of pemphigoid gestationis, even if this localization is commonly observed. The purpuric lesions are unusual because, according to our knowledge, there is no description of purpura associated with palmoplantar lesions in polymorphic eruption of pregnancy. The purpuric lesions may be secondary to high capillary permeability, increased by severe dermic inflammation of the polymorphic eruption of pregnancy and, possibly, high level of circulating estrogens.
authors.affiliation: Service de Dermatologie, Centre Hospitalier Régional d'Orléans, Cedex, France.
authors.forename: F
authors.initials: F
authors.lastname: Normand
authors.forename: P
authors.initials: P
authors.lastname: Armingaud
authors.forename: E
authors.initials: E
authors.lastname: Estève
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000982:Antipruritics / Q000627:therapeutic use; D001623:Betamethasone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D001706:Biopsy; D004359:Drug Therapy, Combination; D011146:Eczema, Dyshidrotic / Q000150:complications* / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D005938:Glucocorticoids; D006801:Humans; D006919:Hydroxyzine / Q000627:therapeutic use; D010298:Parity; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy / Q000473:pathology*; D011537:Pruritus / Q000150:complications* / Q000188:drug therapy / Q000473:pathology*; D011693:Purpura / Q000150:complications* / Q000188:drug therapy / Q000473:pathology*
chemical_list: D000893:Anti-Inflammatory Agents; D000982:Antipruritics; D005938:Glucocorticoids; D006919:Hydroxyzine; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone